Stockscreener 앱 받기
95.41
0.72%
-0.69
시간 외 거래:
94.90
-0.51
-0.53%
전일 마감가:
$96.10
열려 있는:
$95.76
하루 거래량:
2.16M
Relative Volume:
1.01
시가총액:
$18.73B
수익:
$4.58B
순이익/손실:
$870.87M
주가수익비율:
21.69
EPS:
4.3988
순현금흐름:
$945.58M
1주 성능:
-6.94%
1개월 성능:
-11.87%
6개월 성능:
+37.84%
1년 성능:
+34.70%
1일 변동 폭
$93.54
$96.00
1주일 범위
$93.54
$100.43
52주 변동 폭
$53.56
$109.28
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
INCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
95.41 | 18.87B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-08 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 개시 | Barclays | Overweight |
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Incyte Lures New Top Lawyer With Hefty Equity Package Tied to Performance - MyChesCo
Bellevue Group AG Has $106.94 Million Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Corporation (INCY) Announces Retirement of Board Member H - GuruFocus
Incyte director Hervé Hoppenot retires from board effective immediately - Investing.com
Hervé Hoppenot resigns from Incyte’s board of directors - Investing.com
Incyte Announces Change to its Board of Directors - Business Wire
WINTON GROUP Ltd Makes New Investment in Incyte Corporation $INCY - MarketBeat
Ieq Capital LLC Has $27.52 Million Position in Incyte Corporation $INCY - MarketBeat
Incyte’s Blood Cancer Drug Shows Promise, But Hurdles Remain - Finimize
Incyte Corporation $INCY Shares Acquired by Investment Management Corp of Ontario - MarketBeat
Incyte stock rating reiterated by RBC, firm notes ’989 program viability - Investing.com
Jump Financial LLC Purchases 70,768 Shares of Incyte Corporation $INCY - MarketBeat
California Public Employees Retirement System Sells 122,593 Shares of Incyte Corporation $INCY - MarketBeat
Amundi Purchases 101,220 Shares of Incyte Corporation $INCY - MarketBeat
Incyte releases data that shows promise in treating rare blood disease - Delaware Business Now
Sun Pharma Claims New Pill Distinct From Incyte's Hit Drug - Law360
Incyte (NASDAQ:INCY) Upgraded at Mizuho - MarketBeat
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia - BioSpace
Incyte stock holds Market Perform rating at Citizens on CALR therapy lead - Investing.com
Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap? - Yahoo Finance
Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? - Yahoo Finance
Incyte (INCY) Reports Promising Phase 1 Results for INCA033989 i - GuruFocus
Incyte’s experimental drug shows strong response in blood disorder By Investing.com - Investing.com Canada
Incyte’s experimental drug shows strong response in blood disorder - Investing.com
Incyte presents data showing 90% response rate for blood cancer drug - StreetInsider
Institution Moves: Why Incyte Corporation ICY stock stays undervaluedWatch List & Short-Term Trading Alerts - BỘ NỘI VỤ
Incyte (NASDAQ:INCY) Trading Down 6.6%Should You Sell? - MarketBeat
Incyte (INCY) Maintained as Equal-Weight by Morgan Stanley with Raised Price Target | INCY Stock News - GuruFocus
INCY: Wells Fargo Raises Price Target to $116 | INCY Stock News - GuruFocus
Incyte gains FDA Breakthrough designation for its candidate against essential thrombocythemia - marketscreener.com
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status - Yahoo Finance
Incyte (INCY) Stock Receives Upgraded Rating and Price Target fr - GuruFocus
What's Going On With Incyte Stock Monday?Incyte (NASDAQ:INCY) - Benzinga
Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer - Sahm
Leerink Partners Adjusts Incyte Price Target to $128 From $103, Maintains Outperform Rating - marketscreener.com
Incyte stock price target raised to $128 by Leerink on mCALR data - Investing.com
Incyte Corporation $INCY Shares Purchased by American Century Companies Inc. - MarketBeat
Incyte Says Rare Blood Cancer Therapy Receives FDA Breakthrough Designation - marketscreener.com
Incyte Names Veteran Biopharma Attorney as New General Counsel - MyChesCo
Wells Fargo Adjusts Price Target on Incyte to $116 From $97, Maintains Overweight Rating - marketscreener.com
Mizuho upgrades Incyte stock rating to Outperform on promising ASH data - Investing.com
Incyte stock price target raised by BofA to $118 on promising blood disorder data - Investing.com
Mizuho Upgrades Incyte to Outperform From Neutral, Adjusts Price Target to $121 From $90 - marketscreener.com
First Trust Advisors LP Sells 12,101 Shares of Incyte Corporation $INCY - MarketBeat
Transcript : Incyte CorporationSpecial Call - marketscreener.com
Incyte (INCY) Secures FDA Breakthrough Therapy Designation for I - GuruFocus
Incyte (INCY) Reveals Promising Phase 1 Results for INCA033989 i - GuruFocus
Incyte (INCY) Receives FDA Breakthrough Therapy Designation for INCA033989 - GuruFocus
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025 - Yahoo Finance
18,946 Shares in Incyte Corporation $INCY Bought by 1832 Asset Management L.P. - MarketBeat
Incyte: Buy At This Inflection Point (NASDAQ:INCY) - Seeking Alpha
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.07%
0.91%
자본화:
|
볼륨(24시간):